Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
Study on the therapeutic effect of different infusion times on tislelizumab in high-risk postoperative hepatocellular carcinoma
Trial Details
- NCT ID
- NCT07243691
- Phase
- NA
- Sponsor
- Sir Run Run Shaw Hospital
- Status
- RECRUITING
- Cancer Type
- Hepatocellular Carcinoma (HCC) Liver Cancer
- Interventions
- Tislelizumab: 200mg, intravenous infusion, Q3W
- Locations (sample)
- Hangzhou, Zhejiang, China|30.29365,120.16142
Key Eligibility Criteria
- (1) 18\~75 years old (including boundary values).
- (2) The first diagnosis confirmed by histology or cytology is HCC.
- (3) Barcelona Clinical Liver Cancer (BCLC) stage A-B has undergone curative resection of the tumor, with no extrahepatic metastasis or adjacent org…
- (4) Must meet at least one of the high-risk recurrence risk criteria (as follows): Characteristics of high-risk recurrent liver cancer after surger…
For full eligibility, visit ClinicalTrials.gov.